Here are the DEF 14A proxy statements from Chemed Corporation (CHE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CHE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHE filings page.
Chemed Corporation amended its Definitive Proxy Statement to correct the number of shares outstanding: 13,413,917 shares were outstanding and entitled to vote as of March 23, 2026. The amendment is clerical only and makes no other changes to the proxy materials for the Annual Meeting on May 18, 2026.
The Proxy Statement describes the Annual Meeting agenda (elect nine directors; ratify auditors; advisory vote on executive compensation), voting procedures, director nominees and detailed governance and executive compensation policies, including 2025 pay outcomes and equity incentive structures.
Chemed Corporation is asking stockholders to vote at its May 18, 2026 annual meeting on three main items: electing nine directors, ratifying the independent auditor, and approving executive compensation in an advisory vote. Stockholders of record on March 23, 2026, when 14,614,676 shares were outstanding, may vote in person or by mail, phone, or Internet.
The Board uses a majority voting standard in uncontested director elections and all incumbent nominees have pre-submitted resignations if they fail to receive majority support. Non-employee directors receive $80,000 in annual cash retainers plus meeting fees and about $160,394 in fully vested stock awards, with additional retainers for committee roles and the Chair.
For 2025, CEO Kevin J. McNamara’s total compensation was $12.9 million, with roughly 72.9% performance-based. The pay program ties annual bonuses mainly to Adjusted EPS and return on assets, and long-term incentives to three-year cumulative Adjusted EPS and relative Total Shareholder Return versus a defined peer group. In the 2025 say-on-pay vote, 88.63% of shares voting supported Chemed’s executive compensation program.